Institut Régional Cancer Montpellier - ICM Val d'Aurelle — Clinical Trial Site

10 Registered trials

6 Currently recruiting

Organisation

Institut Régional Cancer Montpellier - ICM Val d'Aurelle

Location

MONTPELLIER, France

Identifier

ORL-000004823

Address

208 Avenue des Apothicaires, 34298, France

Departments

Chirurgie
Early clinical trial Unit
Medical Oncology
Oncologie
ONCOLOGIE MEDICALE
oncology

Clinical trials at this site (10)

Search interface

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Patients with DMMR and/or MSI metastatic colorectal can 4
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
First-in-human study of OT-A201 in patients with selected hematological malignancies and solid tumors Recruiting

2024-511936-28-00 Relapsed/refractory hematological malignancies or adva 1 2023-05-12
Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ov… Recruiting

2024-515310-40-01 Patients with a confirmed diagnosis of ovarian small ce 4 2021-08-04
Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting

2024-517390-24-00 Ovarian epithelial cancer : intraperitoneal resectable 5 2011-04-26
START : Study on Androgen Receptor and Triple Negative Breast Cancer Ended

2024-516638-36-00 Triple-negative androgen receptor positive (molecular a 4 2018-03-14
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended

2023-509336-25-00 Metastatic castration-resistant prostate cancer 9 2024-06-12
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc… Ended

2024-515533-15-00 Locally advanced cervical cancer 4